Selleckproductshavebeencitedinover130,000studies
DavidBaker
WontheNobelPrizeinChemistryin2024
KatalinKarikó
WontheNobelPrizeinPhysiologyorMedicinein2023
DavidJulius
WontheNobelPrizeinPhysiologyorMedicinein2021
MichaelHoughton
WontheNobelPrizeinPhysiologyorMedicinein2020
CharlesM.Rice
WilliamG.KaelinJr
WontheNobelPrizeinPhysiologyorMedicinein2019
PeterJ.Ratcliffe
GreggL.Semenza
JamesP.Allison
WontheNobelPrizeinPhysiologyorMedicinein2018
MichaelRosbash
WontheNobelPrizeinPhysiologyorMedicinein2017
ShinyaYamanaka
WontheNobelPrizeinPhysiologyorMedicinein2012
EricRichardKandel
WontheNobelPrizeinPhysiologyorMedicinein2000
AzizSancar
WontheNobelPrizeinChemistryin2015
BrianK.Kobilka
WontheNobelPrizeinChemistryin2012
RobertLefkowitz
AaronCiechanover
WontheNobelPrizeinChemistryin2004
Auniquecollectionof3152approveddrugsandAPIincludedinpharmacopoeiaforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof3603drugsthataremarketedaroundtheworldorhavepassedclinicalphase1andcanbeusedforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof3458preclinicalandclinicalcompoundsforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof9941bioactivecompoundsforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof5309bioactivecompoundsforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof2011kinaseinhibitorsforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof3010chemicalcompoundsfeatureddifferentcorestructuresandstructuraldiversitiesrespectivelyforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
Auniquecollectionof3048naturalproductsforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
842smallcollectionsofhumanendogenousmetabolites,involvingmultiplemetabolicpathways,whichcanbeusedforhigh-throughputscreening,openingupnewwaysforhumanstotreatvariousdiseasessuchastumors.
Auniquecollectionof436alkaloidcompoundsusedforhighthroughputscreening(HTS)andhighcontentscreening(HCS).
G150isapotentandhighlyselectivehumancyclicGMP-AMPsynthase(h-cGAS)inhibitorwithIC50of10.2nM.
TH5487isaselectiveactive-siteinhibitorof8-oxoguanineDNAglycosylase1(OGG1)withIC50of342nM.
KGA-2727isapotent,selective,high-affinityinhibitorofsodiumglucosecotransporter1(SGLT1)withKiof97.4nMand43.5nMforhumanSGLT1andratSGLT1,respectively.Theselectivityratios(KiforSGLT2/KiforSGLT1)ofKGA-2727are140(human)and390(rat).KGA-2727exhibitsantidiabeticefficacyinrodentmodels.
Mizagliflozinisanovel,potent,selectivesodiumglucoseco-transporter1(SGLT1)inhibitorwithKiof27nMforhumanSGLT1.Theselectivityratio(KivalueforhumanSGLT2/KivalueforhumanSGLT1)ofmizagliflozinis303.Mizagliflozinshowsthepotentialusefortheameliorationofchronicconstipation.
Guadecitabine(SGI-110)isanext-generationhypomethylatingagentwhoseactivemetabolitedecitabinehasalongerin-vivoexposuretimethanintravenousdecitabine.
CM-272isanovelfirst-in-classdualreversibleinhibitorofG9a(GLP)andDNMTswithIC50of8nM,382nM,85nM,1200nM,2nMforG9a,DNMT1,DNMT3A,DNMT3B,GLP,respectively.CM-272prolongssurvivalininvivomodelsofhaematologicalmalignanciesbyatleastinpartinducingimmunogeniccelldeath.
INT-777(S-EMCA)isanovelpotentandselectiveTGR5agonistwithEC50valuesof0.18μM,3.9μMand1.45μMforWTTGR5,TGR5(N76A)andTGR5(Y89F)respectively.
BAY1125976isaselectiveallostericAKT1/2inhibitor,exhibitshighefficacyonAKTsignaling-dependenttumorgrowthinmousemodels.BAY1125976inhibitstheactivityofAKT1(IC50=5.2nMat10μMATPand44nMat2mMATP)andAKT2(IC50=18nMat10μMATPand36nMat2mMATP)verypotently.WhereasBAY1125976isalmostinactiveonAKT3(IC50=427nMat10μMATP).